CN106237326B - A kind of pharmaceutical composition containing rhIL-12 treatment inactivity hepatitis B - Google Patents
A kind of pharmaceutical composition containing rhIL-12 treatment inactivity hepatitis B Download PDFInfo
- Publication number
- CN106237326B CN106237326B CN201610773022.0A CN201610773022A CN106237326B CN 106237326 B CN106237326 B CN 106237326B CN 201610773022 A CN201610773022 A CN 201610773022A CN 106237326 B CN106237326 B CN 106237326B
- Authority
- CN
- China
- Prior art keywords
- rhil
- cell
- hepatitis
- pharmaceutical composition
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to field of biological, and in particular to a kind of pharmaceutical composition containing rhIL-12 treatment inactivity hepatitis B.Every milliliter of the pharmaceutical composition aqueous solution containing 10~20 μ g of rhIL-12,10~60 μ g of recombinant HBsAg protein vaccine, mycobacterium vaccae vaccine 5~20 μ g and surplus.The pharmaceutical composition can activated T lymphocytes subgroup, promote CD3+CD4+、CD3+CD8+Cell secretion of gamma-IFN, and inhibit CD3+CD4+、CD3+CD8+Cell expresses PD-1；Can also activated monocyte and Dendritic Cells, promote CD14+Cell and CD1a+Cell expresses Toll-like receptor, enhances specific immunity and non-specific immune function, with break immune tolerance status, preferably healing HBV infection, and HBsAg serum yin is promoted to turn.
Description
Technical field
The present invention relates to field of biological, and in particular to a kind of drug containing rhIL-12 treatment inactivity hepatitis B
Composition.
Background technique
Hepatitis B (hepatitis B) is the common disease in China, has certain caused by hepatitis type B virus (HBV) infection
Infectiousness, wherein hepatitis B patient and HBV carrier are the major source of infection of this disease.Clinical manifestation be out of strength, sitophobia,
The symptoms such as nausea, abdominal distension, hepatalgia, serious person can develop as cirrhosis and liver cancer, seriously affect the health of our people.
Treating hepatitis B mainly includes antiviral, immunological regulation, anti-fibrosis and symptomatic treatment at present.Mostly use nucleosides similar
The drugs such as object, interferon-' alpha ' (IFN-α) and long-acting interferon (PEG IFN-α) carry out single or drug combination, this treatment side
Method can obviously inhibit the DNA replication dna of HBV, and make the stronger hepatitis B virus e antigen of infectiousness (HBeAg) is gradually negative in serum to turn.
To keep impaired liver function recovery normal.But these therapies finally can not all remove the hepatitis B surface antigen in serum
(HBsAg), can not make to generate hepatitis B surface antibody (HBsAb) in serum.Its basic reason is the immune function of the infected
Inhibited by HBsAg.In terms of congenital inherent immunity function, the important protein molecular Toll of nonspecific immune reaction is participated in
The function of sample receptor (TLR3, TLR7) is suppressed, and the lasting presence of HBV makes congenital immunity remove disabler.And acquired
Immunology occurs the program for having negativity adjustment effect to immune response in CD4+, CD8+T cell since HBV persistently exists
Property dead -1 receptor (PD1) and the high expression of its ligand (PDL-1), cause T cell to be changed into and exhaust T cell (T cell
Exhausted) i.e. nonfunctional T cell, prevents it from removing HBV well, can not form immunological memory, to cannot monitor
The generation of HBsAg leads to lasting masculin in the lasting presence and serum of HBsAg.Therefore, under current treatment method treatment,
HBsAg persistently exists and cannot be fully erased.In view of this, congenital inherent immunity and the day after tomorrow can be activated by exploring and finding one kind
Acquired immunity just becomes a urgent and significant job with the drug or treatment method of thoroughly curing hepatitis B.
Chinese patent application 200610123433.1 discloses a kind of therapeutic vaccine composition for hepatitis B, the every milli of the composition
It rises and contains 10~20 μ g recombinant HBsAg protein vaccines, 10~20 μ g recombinant human interleukin-12s, 9~1,800,000,000 Pseudomonas Vaccine systems
The aqueous solution of agent and surplus.The composition of the invention can activate multiple Immune targets such as NKT cell, NK cell, DC and T cell
(CD4+T cell, CD8+T cell, memory t cell), to breaking HBV immune tolerance, reconstituted cell immune function, to inhibiting and
Good result will be generated by removing HBV.
Summary of the invention
In order to solve the problems existing in the prior art, it is non-live containing rhIL-12 treatment that the purpose of the present invention is to provide one kind
The pharmaceutical composition of dynamic property hepatitis B.
The present inventor has found through a large number of experiments, rhIL-12 (rhIL-12) and hepatitis B epidemic disease
Seedling (recombinant HBsAg protein vaccine) and cellular immunity adjuvant (mycobacterium vaccae vaccine) combination, can be improved host to HBV's
Specificity and nonspecific immune reaction, preferably healing HBV infection, and HBsAg serum yin is promoted to turn, it can be used for treatment and be in
Immune tolerance, immune clearance phase or inactivity HBsAg carry the chronic hepatitis B of phase.
Further, it was found by the inventors of the present invention that in the pharmaceutical composition of every milliliter for the treatment of inactivity hepatitis B, each group
Part has preferable therapeutic effect in following concentration ranges, wherein 10~20 μ g of rhIL-12, recombination
5~20 μ g of 10~60 μ g of HBsAg protein vaccine and mycobacterium vaccae vaccine.
Further, it was found by the inventors of the present invention that when the pharmaceutical composition of every milliliter for the treatment of inactivity hepatitis B contains
Therapeutic effect when 10 μ g of rhIL-12, recombinant HBsAg protein vaccine 60 μ g and 10 μ g of mycobacterium vaccae vaccine
Most preferably.
Further, the dosage form of the pharmaceutical composition for the treatment of inactivity hepatitis B of the present invention is liquid drugs injection, described
Liquid drugs injection in for dissolve it is molten used in rhIL-12, recombinant HBsAg protein vaccine and mycobacterium vaccae vaccine
Agent is water for injection or physiological saline.
Further, the dosage form of the pharmaceutical composition for the treatment of inactivity hepatitis B of the present invention is freeze drying powder injection,
Solvent for dissolved freeze-dried powder injection is water for injection or physiological saline.
RhIL-12 of the present invention be it is a kind of both can with the congenital inherent immunity of human activin (such as TLR3, TLR7 and NK are thin
Born of the same parents), and the T cell function of exhausting can be restored, and the cell factor of PD1 can be lowered.RhIL-12 can make the T cell of activation
It is proliferated and increases its cytotoxic activity, induced NK cell and T cell generate a large amount of endogenic gamma interferon (IFN-γ),
This endogenous IFN-γ can enter the duplication and the process of reproduction that liver cell etc. has infected the intracellular prevention HBV of HBV, shape
At intracellular non-cytolytic virus sweep mode, the DNA and HBsAg of the HBV in scavenger-cell.RhIL-12 can also pass through tune
Helper T lymphocyte (Th1/Th2 cell) development is saved, promotes it to Th1 cell differentiation, start and is adjusted is cell-mediated immune anti-
It answers.
Recombinant HBsAg protein vaccine of the present invention is yeast cells, mammalian cell or other available cell tables
The genetic engineering recombinant protein reached, to have medicative specific immunity regulator.The recombinant HBsAg albumen of doses
The prolonged and repeated immune immune response (tending to Th1 type) that body immune system can be induced to generate specificity of vaccine, is raised non-molten
The cellullar immunologic response of cellularity and cytolytic, and the duplication and expression of HBV after HBV infection can be reduced.
Mycobacterium vaccae vaccine of the present invention is bidirectional immune regulator, and there is the enhancing of stronger cellular immunity to make
With the Th1 of specificity capable of being excited immune, and lower Th2, to control immunopathogenesis reaction.Mycobacterium vaccae vaccine pair
Immunologic hypofunction and hyperthyroid play the role of adjusting and treatment, using it as cellular immunity adjuvant, in conjunction with rhIL-12 and again
Group HBsAg protein vaccine implements combined immunization treatment to HBV infection person, can improve the cellular immunity and body of HBV infection person simultaneously
Liquid immune function effectively removes intracorporal HBV with break immune tolerance status, thoroughly cures HBV infection to reach, and make
The purpose that HBsAg serum yin turns.
The present invention is (including immune tolerance, immune clear to Healthy People and chronic hepatitis B patient by exploring rhIL-12
Except the phase, inactivity HBsAg carry the phase) peripheral blood mononuclear cells (Peripheral blood mononuclear
Cells, PBMCs) the case where inducing IFN-γ (mainly being secreted by Th1 cell) and IL-4 (mainly being secreted by Th2 cell), understand
RhIL-12 adjusts the effect of Th1/Th2 cell balance to enhancing chronic hepatitis B patient Th1 predominant expression.The results show that
RhIL-12 promotes Healthy People and immune tolerance, immune clearance phase, inactivity HBsAg carrying phase trouble in dose relationship
The PBMCs of person induces IFN-γ, but induces IL-4 to PBMCs and have no significant effect.The above result shows that rhIL-12 can enhance Th1
The predominant expression of cytokines, it is thin that rhIL-12 all has enhancing to the chronic hepatitis B patient PBMCs of different clinical stages
The effect of born of the same parents' immune function.
Further, the present invention respectively individually answers rhIL-12, recombinant HBsAg protein vaccine, mycobacterium vaccae vaccine
With or combination of two application or three's combined application to evaluate to Healthy People and chronic hepatitis B (CHB) patient
PBMCs induces the influence of IFN-γ, and using anti-human CD3 monoclonal antibody as positive control, determines rhIL-12, recombinant HBsAg albumen epidemic disease
Seedling, mycobacterium vaccae vaccine three enhance the influence that CHB patient PBMCs generates specificity cellular immunity response to HBV antigen.
The results show that recombinant HBsAg protein vaccine, mycobacterium vaccae vaccine individually stimulate Chronic Hepatitis B or Healthy People
When PBMCs, only a small amount of IFN-γ is generated.RhIL-12 stimulation is used alone, the IFN-γ of generation has compared with negative control group
Statistical difference (P < 0.05), but still in reduced levels.Joined with recombinant HBsAg protein vaccine or mycobacterium vaccae vaccine
The PBMCs for closing rhIL-12 stimulation Chronic Hepatitis B and Healthy People has found joint group compared with independent group, and IFN-γ level is all
There is obvious rising, difference is statistically significant (P < 0.01).Joined with recombinant HBsAg protein vaccine and mycobacterium vaccae vaccine
The PBMCs for closing rhIL-12 stimulation Chronic Hepatitis B and Healthy People, has found three kinds of stimulant joint groups and recombinant HBsAg albumen
Vaccine or mycobacterium vaccae vaccine joint two kinds of stimulant joint groups of rhIL-12 compare, and IFN-γ level has obvious rising,
Difference is statistically significant (P < 0.01).The above result shows that rhIL-12, recombinant HBsAg protein vaccine, mycobacterium vaccae
Vaccine triple combination, which applies, has synergistic effect, can significantly increase the cellular immune function of chronic hepatitis B patient PBMCs.
Further, the present invention has also inquired into rhIL-12, recombinant HBsAg protein vaccine, mycobacterium vaccae vaccine three
Use in conjunction induces the influence of the main cell subgroup in IFN-γ source and the expression of PD-1, TLR to healthy volunteer PBMCs.
The results show that health hope person PBMCs through antigen joint rhIL-12 be incubated for after, CD3+CD4+、CD3+CD8+Intracellular secretory IFN-
There were significant differences compared with negative control group for the percentage of cells of γ (P < 0.05)；CD3+CD4+、CD3+CD8+Cell PD-1's
There were significant differences compared with negative control group (P < 0.01) for expression；CD14+The expression and negative control group of cell TLR3, TLR7
Compare that there were significant differences (P < 0.01)；CD1a+The expression of cell TLR3, TLR7 there were significant differences compared with negative control group (P
< 0.01).The above result shows that antigen joint rhIL-12 can activated T lymphocytes subgroup, promote CD3+CD4+、CD3+CD8+
Cell secretion of gamma-IFN, and inhibit CD3+CD4+、CD3+CD8+Cell expresses PD-1；Antigen combines rhIL-12 can also activated mononuclear
Cell and Dendritic Cells (DC cell) promote CD14+Cell and CD1a+Cell expresses Toll-like receptor, enhances specific immunity
And non-specific immune function, break HBV immune tolerance, reconstituted cell immune function will generate well inhibition and removing HBV
Effect.
In addition, mouse species test confirms, recombinant HBsAg protein vaccine or mycobacterium vaccae vaccine is used alone, it is small
Only have a small amount of IFN-γ in mouse serum to generate.Compared with physiological saline group, rhIL-12, which is used alone, can dramatically increase mice serum
The content (P < 0.001) of middle IFN-γ is carried out with recombinant HBsAg protein vaccine and mycobacterium vaccae vaccine joint rhIL-12
Using the content for increasing IFN-γ in mice serum becomes apparent (P < 0.001).
Compared with prior art, present invention has an advantage that the medicine group for the treatment of inactivity hepatitis B of the present invention
Close object can activated T lymphocytes subgroup, promote CD3+CD4+、CD3+CD8+Cell generates a large amount of endogenous IFN-γ, and can press down
CD3 processed+CD4+、CD3+CD8+Cell expresses PD-1, improves acquired immunity function；Can also activated monocyte and dendron shape it is thin
Born of the same parents' (DC cell) promote CD14+Cell and CD1a+Cell expresses Toll-like receptor, improves congenital immunity function；The drug
Composition can break HBV immune tolerance, reconstituted cell immune function, preferably healing HBV infection, and promote HBsAg serum negative
Turn.
Specific embodiment
The present invention is further described below by way of specific embodiment, but the present invention is not limited only to following embodiment.
Embodiment 1rhIL-12 induces the effect of IFN-γ to Healthy People and CHB patient PBMCs
1. testing data: the rhIL-12 in the present embodiment is purchased from Kaitai Biological Technology Co., Ltd., Guangzhou；People's IFN-γ
ELISA kit is purchased from BD/Pharmingen company (Becton Dickinson/Phar Mingen USA)；RPMI-1640
Culture solution, glutamine and Hanks liquid are purchased from GIBCO company (USA)；Glucan cardiografin (Ficoll-Hypaque) is purchased from
Shanghai Hua Jing biotechnology company；Fetal calf serum is purchased from GIBCO.
Screening Healthy People 20, CHB patient 62 (wherein immune tolerance 21, immune clearance phase 22, inactivity
HBsAg carries the phase 19).Wherein, Healthy People selection criteria: HBsAg is negative, and HBsAb is positive.All equal nonjoinders of hepatitis B patient
Hepatitis C infection, all subject ages are 15-55 years old, male or female.
2. test method: taking Healthy People or CHB detection in peripheral blood of patients underwent 5ml, heparin 20U/ml is anticoagulant, through RPMI-1640
After culture medium 1:1 dilution, mononuclearcell (PBMCs) is separated according to a conventional method using Ficoll lymphocyte separation medium, then use
RPMI-1640 basic culture solution is washed twice, and finally the RPMI-1640 with 1ml containing 10% inactivated fetal bovine serum (FBS) suspends thin
Born of the same parents, count cell, and adjustment cell concentration is 2 × 106/ml.Take configured 100 μ l cell suspension that 96 well culture plates are added, then
The 100 μ l rhIL-12 of RPMI-1640 (10%FBS, the room temperature) various concentration diluted is added, and sets the basis RPMI-1640
Culture solution blank control wells and anti-human CD3 monoclonal antibody (eBioscience company) Positive control wells, same concentration stimulation hole are all provided with multiple
37 DEG C, 5%CO are set in hole2After incubator is incubated for 72h, cell-free supernatants, ELISA method measurement are aseptically collected
IFN-γ and IL-4 content, as a result see the table below 1-4.
3. data processing: data are usedIt indicates, duplicate measurements variance analysis is carried out using SPSS13.0 statistical software.It is full
Sufficient homogeneity of variance condition, with ONE-WAY ANOVA；Parameter Conditions are unsatisfactory for, are examined using Kruskal-Wallis, conspicuousness inspection
Standard inspection standard is P < 0.05.
4. test result
1 rhIL-12 of table induces IFN-γ and the influence of IL-4 to Healthy People PBMCs
Note: compared with negative control group,*P < 0.05,***P < 0.001；Compared with rhIL-12 0.01ng/m1 group,#P <
0.05,###P < 0.001.
The results show that rhIL-12 0.01ng/m1,0.1ng/m1 and tri- dosage of 1.0ng/m1 and Healthy People PBMCs are incubated
It is horizontal to educate the IFN-γ generated after 72h, there is dose-dependence.Wherein, 0.1ng/m1 and 1.0ng/m1rhIL-12 group and yin
Property control group compared to there were significant differences (P < 0.05, P < 0.001), compared with 0.01ng/m1rhIL-12 group also have significantly
Difference (P < 0.05, P < 0.001).Each rhIL-12 concentration induces IL-4 no significant difference to PBMCs.
2 rhIL-12 of table induces IFN-γ and the influence of IL-4 to immune tolerance patient PBMCs
Note: compared with negative control group,*P < 0.05,**P < 0.01；Compared with rhIL-12 0.01ng/m1 group,##P <
0.01。
The results show that rhIL-12 0.01ng/m1,0.1ng/m1 and tri- dosage of 1.0ng/m1 and immune tolerance patient
PBMCs be incubated for 72h after the IFN-γ level that generates in apparent dose-effect relationship.Wherein, 0.01ng/m1,0.1ng/m1 and
There were significant differences (P < 0.05, P < 0.01) compared with negative control group for 1.0ng/m1rhIL-12 group, and 1.0ng/
M1rhIL-12 group is compared with 0.01ng/m1rhIL-12 group with significant difference (P < 0.05).Each rhIL-12 concentration is to PBMCs
Induce IL-4 no significant difference.
3 rhIL-12 of table induces IFN-γ and the influence of IL-4 to immune clearance phase patient PBMCs
Note: compared with negative control group,*P < 0.05,***P < 0.001；Compared with rhIL-12 0.01ng/m1 group,##P
< 0.01,###P < 0.001.
The results show that rhIL-12 0.01ng/m1,0.1ng/m1 and tri- dosage of 1.0ng/m1 and immune clearance phase patient
PBMCs be incubated for 72h after the IFN-γ level that generates in apparent dose-effect relationship.Wherein, 0.01ng/m1,0.1ng/m1 and
There were significant differences (P < 0.05, P < 0.001) compared with negative control group for 1.0ng/m1rhIL-12 group, and 0.1ng/
M1rhIL-12 group and 1.0ng/m1rhIL-12 group all had compared with 0.01ng/m1rhIL-12 group significant difference (P < 0.01,
P < 0.001).Each rhIL-12 concentration induces IL-4 no significant difference to PBMCs.
4 rhIL-12 of table carries phase patient PBMCs to inactivity HBsAg and induces IFN-γ and the influence of IL-4
Note: compared with negative control group,**P < 0.01,***P < 0.001；Compared with rhIL-12 0.01ng/m1 group,##P
< 0.01,###P < 0.001.
The results show that rhIL-12 0.01ng/m1,0.1ng/m1 and tri- dosage of 1.0ng/m1 and immune clearance phase patient
PBMCs be incubated for 72h after the IFN-γ level that generates in apparent dose-effect relationship.Wherein, 0.1ng/m1rhIL-12 group and feminine gender
Control group all has significant difference (P < compared to there were significant differences (P < 0.01) compared with 0.01ng/m1rhIL-12 group
0.001).Each rhIL-12 concentration induces IL-4 no significant difference to PBMCs.
In conclusion rhIL-12 promotes Healthy People and immune tolerance, the immune clearance phase, non-live in dose relationship
The PBMCs that dynamic property HBsAg carries phase hepatitis B patient induces IFN-γ, but induces IL-4 to PBMCs and have no significant effect.rhIL-12
The predominant expression of Th1 cytokines can be enhanced, rhIL-12 is equal to the chronic hepatitis B patient PBMCs of different clinical stages
Have the function of enhancing cellular immune function.
Embodiment 2rhIL-12 and specific antigen use in conjunction generate the influence of IFN-γ to BALB/c mouse
1. testing data: the rhIL-12 in the present embodiment is purchased from Kaitai Biological Technology Co., Ltd., Guangzhou；RPMI
1640 basic culture solutions, FBS are purchased from GIBCO company (USA)；Ficoll lymphocyte separation medium is purchased from the smart biotechnology of Shanghai China
Company.
Cleaning grade BALB/c mouse 40, half male and half female, weight 20g is purchased from Nanfang Medical Univ's Experimental Animal Center.
2. test method:
40 mouse are randomized into physiological saline group (150 μ l/ of physiological saline is only) and rHBsAg group (10 μ g/ are only), mother
Mycobacterium bovis group (10 μ g/ are only), rhIL-12 group (0.3 μ g/ is only), rHBsAg (10 μ g/ are only)+mycobacterium vaccae (10 μ g/
Only)+rhIL-12 (0.3 μ g/ is only) group, totally five groups, every group 8, half male and half female.It is administered twice, is given again after 72h is administered for the first time
Medicine is primary.Injection site is that mouse the nape of the neck is subcutaneous.Before administration, 24,72h and second of administration after being administered for the first time
Eye socket is taken a blood sample for 24 hours afterwards, and separation serum detects IFN-γ concentration, the results are shown in Table 5.
3. data processing: data are usedIt indicates, duplicate measurements variance analysis is carried out using SPSS13.0 statistical software.It is full
Sufficient homogeneity of variance condition, with ONE-WAY ANOVA；Parameter Conditions are unsatisfactory for, are examined using Kruskal-Wallis, conspicuousness inspection
Standard inspection standard is P < 0.05.
4. test result
5 rmIL-12 of table influences generation IFN-γ in BALB/c mouse serum
Note: compared with physiological saline group,***P < 0.001；Compared with rhIL-12 group,#P < 0.05,##P < 0.01.
The results show that the concentration of IFN-γ peaks for 24 hours in mice serum after administration, rmIL-12 group and rHBsAg+
Mycobacterium vaccae+rhIL-12 group and the obvious raising (P < 0.001) of physiological saline group.IFN- when to 72h in serum
γ restores horizontal close to before administration.Be administered once again at this time, for 24 hours when rmIL-12 group and rHBsAg+ mycobacterium vaccae+rhIL-
IFN-γ and the obvious raising (P < 0.001) of physiological saline group in 12 groups of serum.
Embodiment 3rhIL-12 and specific antigen use in conjunction generate IFN-γ to Healthy People and CHB patient PBMCs
Effect
1. testing data: the rhIL-12 in the present embodiment is purchased from Kaitai Biological Technology Co., Ltd., Guangzhou；RHBsAg purchase
From the safe Biotechnology Co., Ltd in Shenzhen；Injection mycobacterium vaccae is purchased from the limited public affairs of Anhui intelligence flying dragon section horse bio-pharmaceuticals
Department；People's IFN-γ ELISA kit is purchased from BD company.
Screening Chronic Hepatitis B 15, it is the age 17-49 years old, 31.17 years old average.All patients exclude hepatitis A virus
(HAV), Hepatitis C Virus (HCV), Hepatitis D virus (HDV), Hepatitis E virus (HEV) infection and other reasons (medicine
Object, alcohol, poisoning) etc. caused by acute and chronic hepatic lesion.Optionally take 9 healthy volunteers as control, control group is all inoculated with
Cross recombinant HBsAg vaccine, in serum other than HBsAb is positive, remaining HBV serological index is feminine gender.
2. test method: the isolation and culture method of Healthy People and hepatitis B patient PBMCs are the same as embodiment 1.The training of 96 hole cells
Support the every Kong Zhonghan cell suspension of plate and each 100 μ l of respective concentration stimulant, each stimulant concentration and be all provided with 3 multiple holes, set 37 DEG C,
5%CO2Incubator culture 72h, ELISA measure the concentration of IFN-γ in culture supernatant.Wherein, the administration concentration of each group is as follows:
(1) negative control: culture solution；
(2)rHBsAg(0.5μg/ml)；
(3) mycobacterium vaccae (0.225 μ g/ml)
(4)rhIL-12(1ng/ml)；
(5) rHBsAg (0.5 μ g/ml) combines rhIL-12 (1ng/ml)；
(6) mycobacterium vaccae (0.225 μ g/ml) joint rhIL-12 (1ng/ml)；
(7) rHBsAg (0.5 μ g/ml), mycobacterium vaccae (0.225 μ g/ml) joint rhIL-12 (1ng/ml)；
(8) positive control: the anti-human CD3 monoclonal antibody of 0.2 μ g/ml.
As a result 6 be see the table below.
3. data processing: data are usedIt indicates, duplicate measurements variance analysis is carried out using SPSS13.0 statistical software.It is full
Sufficient homogeneity of variance condition, with ONE-WAY ANOVA；Parameter Conditions are unsatisfactory for, are examined using Kruskal-Wallis, conspicuousness inspection
Standard inspection standard is P < 0.05.
4. test result
6 rhIL-12 of table joint antigen therapy induces IFN-γ and the influence of IL-4 to Healthy People and CHB patient PBMCs
| Group | Healthy People | CHB patient |
| Negative control (culture solution) | 7.94±6.19 | 117.40±108.52 |
| rHBsAg | 38.83±26.88 | 105.00±97.35 |
| Mycobacterium vaccae | 53.64±46.82 | 107.48±106.71 |
| rhIL-12 | 153.92±117.84* | 693.35±610.48* |
| rHBsAg+rhIL-12 | 414.66±158.66##△△■■ | 2382.93±1089.27##△△■■ |
| Mycobacterium vaccae+rhIL-12 | 293.66±173.10##△△■■ | 1441.45±1034.16##△△■■ |
| RHBsAg+ mycobacterium vaccae+rhIL-12 | 761.72±546.53★★☆☆ | 3934.27±2434.75★★☆☆ |
| Anti-human CD3 monoclonal antibody | 13246.45±11092.82 | 14605.66±12465.30 |
Note: compared with negative control group,*P < 0.05；Compared with rHBsAg group,##P < 0.01；With mycobacterium vaccae group
Compare,△△P < 0.01；Compared with rhIL-12 group,■■P < 0.01；Compared with rHBsAg+rhIL-12 group,★★P < 0.01；With
Mycobacterium vaccae+rhIL-12 group compares,☆☆P < 0.01.
The results show that individually stimulating CHB patient with 0.5 μ g/ml rHBsAg, 0.225 μ g/ml mycobacterium vaccae or being good for
When the PBMCs of health people, the only a small amount of IFN-γ of discovery is generated.RhIL-12 (1ng/ml) stimulation, the IFN-γ of generation is used alone
There is statistical difference (P < 0.05) compared with negative control group, but IFN-γ is in reduced levels.
With rHBsAg (0.5 μ g/ml) or mycobacterium vaccae (0.225 μ g/ml) joint rhIL-12 (1ng/ml) stimulation
CHB patient and Healthy People PBMCs have found joint group compared with independent group, and IFN-γ level has obvious rising, and difference has statistics
It learns meaning (P < 0.01).
With rHBsAg (0.5 μ g/ml) and mycobacterium vaccae (0.225 μ g/ml) joint rhIL-12 (1ng/ml) stimulation
CHB patient and Healthy People PBMCs have found three kinds of stimulant joint groups and HBsAg (0.5 μ g/ml) or mycobacterium vaccae
(0.225 μ g/ml) joint rhIL-12 (1ng/ml) two kinds of stimulant joint groups compare, and IFN-γ level has obvious rising, poor
Different statistically significant (P < 0.01).
It acts synergistically the above result shows that rhIL-12, rHBsAg, mycobacterium vaccae vaccine triple combination apply to have,
The cellular immune function of CHB patient PBMCs can be significantly increased.
The main cell that embodiment 4rhIL-12 and specific antigen use in conjunction induce IFN-γ source to Healthy People is sub-
The expression study of group and PD-1, TLR
1. testing data: the rhIL-12 in the present embodiment is purchased from Kaitai Biological Technology Co., Ltd., Guangzhou；RPMI
1640 basic culture solutions, FBS are purchased from GIBCO company (USA)；Ficoll lymphocyte separation medium is purchased from the smart biotechnology of Shanghai China
Company；CD3PE,CD8FITC,CD4PreCP,CD1aPE,CD14PE,IFN-γAPC,PD-1APC,TLR3Alexa flour
647, TLR7Alexa flour 488 is purchased from U.S. company BD.
Healthy volunteer 8 are recruited, once inoculated hepatitis B vaccine, HBV serological index are as follows: HBsAg (-), Anti-HBsAg antibody
(+), HBeAg (-), anti-Be (-), Anti-HBc Serum (-).It is sterile to adopt venous blood 10ml.
2. test method:
(1) the isolation and culture method of Healthy People PBMCs is the same as embodiment 1.
It (2) is 2 × 10 by concentration6The cell of/ml is separately added into 2 pipe 15ml cell centrifuge tubes, and every pipe 1ml is divided to two
Group, wherein one group of addition rHBsAg (0.5 μ g/ml), mycobacterium vaccae (0.225 μ g/ml) joint rhIL-12 (1ng/ml),
Another group is done negative control, is mixed, 37 DEG C, 5%CO2Incubate 6h.
(3) it is incubated to last 2h and adds 10 μ l/ml of Protein transport inhibitor (BFA), mix.
(4) cell is washed 2 times (1000r/min, 5min) with PBS, is blotted post-reinforcing with paper and is determined liquid, every pipe adds 4%PFA
(paraformaldehyde) 2ml is mixed, room temperature 8 minutes.
(5) it is washed 2 times (2000r/min, 10min) with PBS, is blotted with paper, respectively plus rupture of membranes agent (buffer 3) 400 μ l, 4 DEG C
Overnight.
(6) it dyes: every pipe four combinations, every group of 100 μ l cells.CD3 antibody, the PreCP mark of first group of addition PE label
The IFN-γ antibody that the CD4 antibody of note, the CD8 antibody of FITC label, APC are marked；The CD3 antibody of second group of addition PE label,
The PD-1 antibody that the CD4 antibody of PreCP label, the CD8 antibody of FITC label, APC are marked；Alexa flour is added in third group
The TLR3 antibody that the TLR7 antibody of 488 labels, the CD1a antibody of PE label, Alexa flour 647 are marked；4th group of addition
The TLR3 antibody that CD14 antibody, the Alexa flour 647 of TLR7 antibody, PE label that Alexa flour 488 is marked are marked.
Every kind of antibody additional amount is 5 μ l.It 4 DEG C, is protected from light 30 minutes.
(7) it is washed 2 times with rupture of membranes agent (buffer 3).
(8) every pipe adds the 300 μ l of PBS containing 0.1%BSA, and cell, upper machine analysis is resuspended.With the analysis of lymphocyte gating
The expression of T cell subgroup IFN-γ and PD-1, respectively with the table of monocyte and Dendritic Cells (DC cell) gating analysis TLR
It reaches.
It the results are shown in Table 7-8.
3. data processing: data are usedIt indicates, duplicate measurements variance analysis is carried out using SPSS13.0 statistical software.It is full
Sufficient homogeneity of variance condition, with ONE-WAY ANOVA；Parameter Conditions are unsatisfactory for, are examined using Kruskal-Wallis, conspicuousness inspection
Standard inspection standard is P < 0.05.
4. test result
The expression of 7 Healthy People PBMCs of table T cell subgroup IFN-γ and PD-1 after antigen joint rhIL-12 is incubated for 6h
(%)
Note: compared with negative control group,*P < 0.05,**P < 0.01.
The expression of 8 Healthy People PBMCs of table monocyte and dendritic cells TLR after antigen joint rhIL-12 is incubated for 6h
(%)
Note: compared with negative control group,*P < 0.05,**P < 0.01.
The results show that healthy volunteer PBMCs through antigen joint rhIL-12 be incubated for after, CD3+CD4+、CD3+CD8+Cell
There were significant differences compared with negative control group for the percentage of cells of endocrine IFN-γ (P < 0.05)；CD3+CD4+、CD3+CD8+
There were significant differences compared with negative control group for the expression of cell PD-1 (P < 0.01)；CD14+The expression of cell TLR3, TLR7 with
Negative control group compares that there were significant differences (P < 0.01)；CD1a+The expression of cell TLR3, TLR7 have compared with negative control group
Significant difference (P < 0.01).The above result shows that the pharmaceutical composition for the treatment of inactivity hepatitis B of the present invention can activate
T lymphocyte subgroup improves acquired immunity function；Can also activated monocyte and Dendritic Cells (DC cell), improve first
Its immune function；The pharmaceutical composition can break HBV immune tolerance, reconstituted cell immune function, preferably healing HBV sense
Dye, and HBsAg serum yin is promoted to turn.
The above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
Limitation of the invention, protection scope of the present invention should be defined by the scope defined by the claims..For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, several improvements and modifications can also be made, these change
It also should be regarded as protection scope of the present invention into retouching.
Claims (4)
1. a kind of pharmaceutical composition of the treatment inactivity hepatitis B containing rhIL-12, which is characterized in that every milliliter
Contain 10~20 μ g of rhIL-12,10~60 μ g of recombinant HBsAg protein vaccine, cow branch bar in pharmaceutical composition
The aqueous solution of bacteria vaccine 5~20 μ g and surplus；The aqueous solution is water for injection or physiological saline.
2. the pharmaceutical composition for the treatment of inactivity hepatitis B according to claim 1, which is characterized in that every milliliter of medicine group
It closes in object containing 10 μ g of rhIL-12,60 μ g of recombinant HBsAg protein vaccine, 10 μ g of mycobacterium vaccae vaccine and remaining
The aqueous solution of amount；The aqueous solution is water for injection or physiological saline.
3. the pharmaceutical composition for the treatment of inactivity hepatitis B according to claim 1 or 2, which is characterized in that the drug
Composition is made into liquid drugs injection or freeze drying powder injection.
4. the pharmaceutical composition for the treatment of inactivity hepatitis B according to claim 3, which is characterized in that the liquid drugs injection
Solvent is water for injection or physiological saline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610773022.0A CN106237326B (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition containing rhIL-12 treatment inactivity hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610773022.0A CN106237326B (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition containing rhIL-12 treatment inactivity hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106237326A CN106237326A (en) | 2016-12-21 |
| CN106237326B true CN106237326B (en) | 2019-11-22 |
Family
ID=58080636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610773022.0A Active CN106237326B (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition containing rhIL-12 treatment inactivity hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106237326B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1429625A (en) * | 2003-01-29 | 2003-07-16 | 田庚善 | Medicine for treating chronic hepatitis B |
| CN1966078A (en) * | 2006-11-10 | 2007-05-23 | 张宜俊 | Therapeutic vaccine composition for hepatitis B |
-
2016
- 2016-08-30 CN CN201610773022.0A patent/CN106237326B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1429625A (en) * | 2003-01-29 | 2003-07-16 | 田庚善 | Medicine for treating chronic hepatitis B |
| CN1966078A (en) * | 2006-11-10 | 2007-05-23 | 张宜俊 | Therapeutic vaccine composition for hepatitis B |
Non-Patent Citations (2)
| Title |
|---|
| 冻干治疗用母牛分枝杆菌菌苗治疗慢性乙型肝炎疗效分析;吴英梅等;《药物流行病学杂志》;20051231;第14卷(第3期);132-133、147 * |
| 母牛分枝杆菌疫苗与乙肝疫苗联合免疫对慢性乙肝患者效果观察;胡莹等;《江苏预防医学》;20091231;第20卷(第4期);11-13 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106237326A (en) | 2016-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Coccia et al. | Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity | |
| Du et al. | Astragalus polysaccharides enhance immune responses of HBV DNA vaccination via promoting the dendritic cell maturation and suppressing Treg frequency in mice | |
| Halperin et al. | Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age | |
| Kapp et al. | GENETIC CONTROL OF IMMUNE RESPONSES IN VITRO: II. Cellular Requirements for the Development of Primary Plaque-Forming Cell Responses to the Random Terpolymer l-Glutamic acid60-l-Alanine30-l-Tyrosine10 (GAT) by Mouse Spleen Cells In Vitro | |
| CN107007626A (en) | Method and composition for cell therapy | |
| US8389479B2 (en) | Compositions and methods for treatment of multiple sclerosis | |
| US20220211840A1 (en) | Composition for treating and/or preventing hepatitis b virus infection and the use thereof | |
| Wei et al. | Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection | |
| Yang et al. | Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy | |
| Ono et al. | Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients | |
| Aricò et al. | Exploiting natural antiviral immunity for the control of pandemics: lessons from Covid-19 | |
| Cadar et al. | Targeting the hallmarks of aging to improve influenza vaccine responses in older adults | |
| CN100391536C (en) | Therapeutic vaccine composition for hepatitis B | |
| CN107174659A (en) | A kind of novel drugs for treating chronic hepatitis B | |
| CN106237326B (en) | A kind of pharmaceutical composition containing rhIL-12 treatment inactivity hepatitis B | |
| Gentili et al. | Natural killer cells in SARS-CoV-2-vaccinated subjects with increased effector cytotoxic cd56dim cells and memory-like CD57+ NKG2C+ CD56dim cells | |
| BEVER JR et al. | A comparison of interferon responses to poly ICLC in males and females | |
| US11771759B2 (en) | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use | |
| CN107812186B (en) | Application of C-type CpG as adjuvant in HBV preventive and therapeutic vaccines and preparation method thereof | |
| CN106581672A (en) | RhIL-12 containing medicine composition for treating non-active hepatitis B | |
| WO2018166298A1 (en) | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use | |
| CN1165343C (en) | Indications for use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses | |
| CN1814285A (en) | Vaccine composition for treating B-type hepatitis and preparing method | |
| Adlard et al. | Immunoregulation of encephalitogenic MBP-NAc1-11-reactive T cells by CD4+ TCR-specific T cells involves IL-4, IL-10 and IFN-γ | |
| CN101686992B (en) | Use of extractive of BCG polysaccharide and nucleic acid for preparing medicine for treating allergic dermatosis, and its injection and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |